Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
This study has been completed.
First Received: January 12, 2004   Last Updated: March 18, 2009   History of Changes
Sponsor: AstraZeneca
Information provided by: AstraZeneca
ClinicalTrials.gov Identifier: NCT00075959
  Purpose

This study will determine if NXY-059 is safe in patients with an acute stroke caused by bleeding in the central nervous system. The primary objective was to assess the safety and tolerability of NXY-059 compared to placebo.


Condition Intervention Phase
Intracerebral Hemorrhage
 Drug: NXY-059
 Phase II

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Factorial Assignment, Safety/Efficacy Study
Official Title: CHANT (Cerebral Hemorrhage And NXY Treatment) A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter, Phase IIb Study to Assess the Safety and Tolerability of Intravenous Infusion of NXY-059 in Adult Patients With Acute Intracerebral Hemorrhage (ICH)

Resource links provided by NLM:

Drug Information available for: Disufenton sodium
U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Global disability on modified Rankin scale at 90 days

Secondary Outcome Measures:
  • NIH stroke scale
  • Barthel Index
  • Stroke Impact Scale

Estimated Enrollment: 600
Study Start Date: July 2004
Study Completion Date: January 2006
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males and females
  • Intracerebral Hemorrhage as the cause of stroke symptoms
  • Onset of symptoms within 6 hours
  • Full functional independence prior to the present stroke

Exclusion Criteria:

  • Unconsciousness
  • Subjects who are unlikely to complete the infusion of investigational product and/or are unlikely to undergo active medical management during that period due to a severe clinical condition.
  • Severe illness with life expectancy less than 6 months.
  • Known severe kidney disorder.
  • Current known alcohol or illicit drug abuse or dependence.
  • Pregnant or breast-feeding.
  • Treatment with acetazolamide and methotrexate is not permitted during the infusion
  • Participation in a previous clinical study within 7 days.
  • Meets all other exclusion criteria
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00075959

  Hide Study Locations
Locations
United States, Alabama
Research Site
Birmingham, Alabama, United States
United States, Arizona
Research Site
Scottsdale, Arizona, United States
United States, Arkansas
Research Site
Fort Smith, Arkansas, United States
United States, California
Research Site
San Jose, California, United States
Research Site
Sacramento, California, United States
Research Site
Santa Rosa, California, United States
Research Site
San Diego, California, United States
Research Site
Walnut Creek, California, United States
Research Site
Carmichael, California, United States
United States, Connecticut
Research Site
Danbury, Connecticut, United States
United States, Florida
Research Site
Tampa, Florida, United States
Research Site
Melbourne, Florida, United States
Research Site
Ocala, Florida, United States
Research Site
Port Charlotte, Florida, United States
Research Site
Punta Gorda, Florida, United States
Research Site
Pompano Beach, Florida, United States
Research Site
Weston, Florida, United States
United States, Georgia
Research Site
Atlanta, Georgia, United States
Research Site
Decatur, Georgia, United States
Research Site
Lawrenceville, Georgia, United States
Research Site
Duluth, Georgia, United States
United States, Hawaii
Research Site
Honolulu, Hawaii, United States
United States, Illinois
Research Site
Arlington Heights, Illinois, United States
Research Site
Maywood, Illinois, United States
United States, Indiana
Research Site
Fort Wayne, Indiana, United States
United States, Iowa
Research Site
Des Moines, Iowa, United States
United States, Kentucky
Research Site
Louisville, Kentucky, United States
United States, Louisiana
Research Site
Shreveport, Louisiana, United States
Research Site
Marrero, Louisiana, United States
United States, Massachusetts
Research Site
South Weymouth, Massachusetts, United States
Research Site
Worcester, Massachusetts, United States
United States, Michigan
Research Site
Ann Arbor, Michigan, United States
Research Site
East Lansing, Michigan, United States
United States, Minnesota
Research Site
Robbinsdale, Minnesota, United States
United States, Missouri
Research Site
Kansas City, Missouri, United States
United States, Nebraska
Research Site
Omaha, Nebraska, United States
United States, Nevada
Research Site
Reno, Nevada, United States
United States, New Jersey
Research Site
Edison, New Jersey, United States
Research Site
Ridgewood, New Jersey, United States
Research Site
Morristown, New Jersey, United States
Research Site
Summit, New Jersey, United States
Research Site
Holmdel, New Jersey, United States
United States, New York
Research Site
Schenectady, New York, United States
Research Site
Manhasset, New York, United States
United States, North Carolina
Research Site
Durham, North Carolina, United States
Research Site
Winston Salem, North Carolina, United States
United States, Ohio
Research Site
Cleveland, Ohio, United States
Research Site
Akron, Ohio, United States
Research Site
Toledo, Ohio, United States
Research Site
Youngstown, Ohio, United States
United States, Oklahoma
Research Site
Oklahoma City, Oklahoma, United States
United States, Pennsylvania
Research Site
Philadelphia, Pennsylvania, United States
Research Site
Pittsburgh, Pennsylvania, United States
Research Site
Hershey, Pennsylvania, United States
Research Site
Danville, Pennsylvania, United States
Research Site
Abington, Pennsylvania, United States
United States, Tennessee
Research Site
Memphis, Tennessee, United States
Research Site
Bristol, Tennessee, United States
United States, Texas
Research Site
Houston, Texas, United States
Research Site
Lubbock, Texas, United States
United States, Virginia
Research Site
Virginia Beach, Virginia, United States
United States, Washington
Research Site
Olympia, Washington, United States
United States, Wisconsin
Research Site
Marshfield, Wisconsin, United States
Research Site
Madison, Wisconsin, United States
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: AstraZeneca NXY-059 Medical Science Director, MD AstraZeneca
  More Information

No publications provided

Study ID Numbers: SA-NXY-0012, 0012, CHANT
Study First Received: January 12, 2004
Last Updated: March 18, 2009
ClinicalTrials.gov Identifier: NCT00075959     History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by AstraZeneca:
Stroke
cerebral vascular accident
CVA
Hemorrhage
 Intracerebral Hemorrhage (ICH)
Brain Attack
Cataplexy

Additional relevant MeSH terms:
Cerebral Hemorrhage
Antioxidants
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Nervous System Diseases
Vascular Diseases
Central Nervous System Diseases
Disufenton sodium
Intracranial Hemorrhages
 Cardiovascular Agents
Hemorrhage
Brain Diseases
Protective Agents
Cerebrovascular Disorders
Pharmacologic Actions
Pathologic Processes
Therapeutic Uses
Cardiovascular Diseases

ClinicalTrials.gov processed this record on November 30, 2009



Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services